Press release content from Business Wire. The AP news staff was not involved in its creation.
iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)
February 9, 2021 GMT
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy® validation. The study is related to the iBiopsy® NASH Clinical Development Plan (CDP).
It is estimated that NASH is affecting 1.5-6.45 % of the global population 1.
(1)
The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients
The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy s AI technology, applied to liver fibrosis characterization
The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) NASH
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy validation. The study is related to the iBiopsy NASH Clinical Development Plan (CDP).